Last reviewed · How we verify
zilucoplan (RA101495)
Zilucoplan is a sphingosine 1-phosphate receptor modulator.
Zilucoplan is a sphingosine 1-phosphate receptor modulator. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | zilucoplan (RA101495) |
|---|---|
| Sponsor | UCB Biopharma SRL |
| Drug class | S1P receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to sphingosine 1-phosphate receptor 1 (S1P1), which is involved in the regulation of immune cell trafficking and activation. By modulating this receptor, zilucoplan aims to reduce inflammation and autoimmune responses.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Fatigue
- Injection site reactions
Key clinical trials
- A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis (PHASE3)
- An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (PHASE3)
- A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (PHASE2, PHASE3)
- A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women (PHASE1)
- Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (PHASE3)
- A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants (PHASE1)
- An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors (PHASE3)
- Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- zilucoplan (RA101495) CI brief — competitive landscape report
- zilucoplan (RA101495) updates RSS · CI watch RSS
- UCB Biopharma SRL portfolio CI